It is presumed that the medical device industries will be followed by pharmaceutical industries in terms of AAALAC accreditation. The safety test will be internationalized and the national background such as its own history and culture may not be counted in this sense. ISO/TC194 was created in 1988. From the 2 nd ISO/ TC194 general meeting at Bordeaux in France., the standard was discussed. The first edition was published in 1992. In 2006, the major revision was made including definition of alternatives and detailed definition s of 3Rs. The most recent revision of ISO 10993-2 describes not only laboratory animal welfare Implantation test with laboratory animals is a unique test method widely used for medical devices. It is intended to evaluate or determine effects on surrounding tissue after implantation of test materials into animal body. The standard methods are known; for internationally, ISO 10993-6（2016） Tests for local effects after implantation, and in Japan, Yakushokukihatsu 0301 No.20（2012） Attachment: Guidance on test methods for biological safety evaluation of medical devices, part 4. This test aims to evaluate the local effects of the implanted specimens by their characteristics of materials, surface, degradation process regarding type and degree of surrounded tissue reactions, but not to evaluate the effect by the design specification except for the case when final products are implanted as clinical simulation. In test design, test animals, implantation sites, test periods, and detailed methods should be considered for safety test but also for their development process and training activities. It should be emphasized that the international standard of clinical and biological safety of cells and tissues derived from human are also standardized by ISO/TC194. The revisions will be made should be also discussed. The US FDA proposed amendment of GLP regulation in animal welfare which are revised to accord with US animal welfare act and ILAR Guide. These are already discussed within ISO/TC194 WG3. One of the reference article of ISO 10993-2 is OIE terrestrial animal health code and the part of animal welfare is accepted by ISO/TS34700:2016.
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depending on clinical use of the final product according to testing guidelines. For degradable materials, test period shall be enough to assess decomposed process since various substances, produced by breaking into small pieces or eluting, makes circumstance of surrounding tissue change. Thus, three time points, early, mid and late time frames, shall be included. Recently, cellular and tissue-based products are researched and developed throughout the world. For evaluation of local effects on transplanted sites of these new products, immunodeficient animal models shall be used to avoid rejection of the transplanted products, although availability of these immunodeficient models for evaluating local and systemic reactions have not been fully characterized. Thus, further research should be needed to develop suitable animal models. Currently, biological safety evaluation of medical devices is performed in accordance with 3 guidelines, such as the domestic guidance, ISO 10993-1 and FDA guidance. The guidelines have their own special features; however, their basis is ISO 10993-1. The requirements for test items of the three legislative jurisdictions are similar; however, each regulation has regionally specified requirements. In addition, with social interest in animal welfare being higher, promotion of 3Rs is getting requested lately. Among the test times, in vitro alternative test methods to in vivo sensitization, irritation and acute systemic toxicity tests have been developed. Due to the special characteristics of medical devices, not all the test methods included in the OECD can be adopted in ISO 10993 series.
ISO/TC194 Biological and Clinical Evaluation of Medical Devices；Animal Welfare
Recently, with the progress of the development of high performance medical devices, requirement of regulatory approval application has increased. For example, U.S. FDA issued "General Consideration for Animal Studies for Medical Devices. October 14, 2015" , requires GLP application, raises the request for science and assurance. From this, the development of medical devices, not only the safety but also in proof of performance and handling, imitation of clinical use of animal evaluation becomes important. As for medical devices, there are catheter which are used for short period of time in human body, stent and vascular grafts that are implanted in the body for one' s life time, which shows a variety of usage and characteristics in products. So that safety and performance evaluation must reflect characteristics of Finally, the recent trend of ISO 10993 series is briefly explained. Within the next fiscal year, ISO 10993-10 is targeting to include an alternative test method to irritation study that uses a three-dimensional cultured skin model. Validation of an alternative test to a sensitization test has been started, as well. As the next evaluation method to alternative test methods, evaluation based on chemical characterization has been reviewed. Evaluation items listed in ISO 10993-1 as the general principles are now under discussion about modifying them based on the FDA guidance. Related to this trend, robust future discussions about how to adopt it in our domestic guidance, including relationship between ISO 10993 and JIS are necessary. medical devices. Especially, choice of animal models is important. In performance evaluation in catheter and stent pig is widely used. Because size and structure of heart, and blood vessel running is similar to human, it can evaluate product itself in a same operative way as to clinical usage. As for evaluation of medical devices in same operative way as to clinical usage, in clinical settings, it becomes extremely important when verify whether medical devices run safely and effectively as intended design. In this symposium, I' d like to show performance evaluation specific to medical devices evaluation, at the same time introduce latest evaluation technique using diagnostic imaging catheter and stent. Also, I will introduce histopathological examination of medical devices made of metal and polymer materials.
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○ Yukiko Kanazawa
Division of Safety, Hatano Research Institute, Food and Drug Safety Center
Animal studies of technology specific to medical device evaluation
○ Masashige Sasaki
Terumo Cooperation, R&D Center, Evaluation Center
S5-3
S5-4
In order for medical device with state-of-the-art technology and novel mechanism of action to be used in the medical practice, the effectiveness and safety of the product are evaluated by regulatory authorities, and applicant have to get approval or notification on the market. For developing new materials and stateof-the-art technologies, researchers have to understand the regulation of medical devices, and develop the strategic action plan to the market. Focusing on the implementation of clinical investigation, Phase I, II and III are conducted for pharmaceuticals after completing non-clinical study, whereas Pivotal clinical investigation is generally conducted after completing Feasibility or Pilot clinical investigation in medical devices. Furthermore, premarket approval or notification of medical device is applied from the classification by risk: registration for low risk medical devices, premarket notification for medium risk device, and premarket approval for high risk product.
In this presentation, I outline the definition, and classification of medical devices as well as regulation of medical devices in the US, EU and Japan in the first part. I also review the regulation through product life cycle and product development in the second part. Finally, I consider the current direction which key stakeholders of medical devices are eager to find the quickest way to provide the medical device on the market, and furthermore mention the example such animal explanation as alternative study instead of human clinical investigation. Therefore, we have to cultivate human resource capable of evaluating or determining the medical device with state-of-the-art technology and novel mechanism of action in the field of regulatory science.
Reference: Medical devices regulation and regulatory science in Japan, the United States and the European Union. Biomaterials, 2015, 33(1):85-92 (in Japanese)
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